Invasive candidiasis: update on current pharmacotherapy options and future perspectives

Tragiannidis, Athanasios; Tsoulas, Christos; Kerl, Kornelius; Groll, Andreas H.

doi:10.1517/14656566.2013.805204

Cited by 29 publications

(18 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Invasive candida infections (ICI) are one of the important causes of morbidity and mortality in immunosuppressed individuals and in hospitalized patients (1). Newborns, patients in intensive care units (ICU) and hematology-oncology wards, and patients who have undergone bone marrow transplantation are especially at risk in terms of invasive candidiasis.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Candida species and antifungal susceptibilities among children with invasive candidiasis

et al. 2017

View full text Add to dashboard Cite

Aim: Non-albicans Candida species and resistant microorganisms have been more commonly isolated in invasive candidiasis in recent years. The aim of this study was to evaluate the distrubution of Candida spp and antifungal resistance in our clinic. Material and Methods: Fifty-four Candida isolates and antifungal susceptibility results obtained from patients diagnosed as having invasive candidiasis between December 2012 and June 2016 were included. Clinical and laboratory data were retrospectively analyzed. E-test method was used in order to determine antifungal susceptibilities of Candida spp for amphotericin B, fluconazole, voriconazole, ketoconazole, itraconazole, anidulafungin, caspofungin, and flucytosine. Results: The clinical diagnoses of the patients were candidemia (n=27, 50%), catheter-related blood stream infection (n=1, 1.8%), urinary tract infection (n=13, 24%), surgical site infection (n=4, 7.4%), intraabdominal infection (n=3, 5.5%), empyema (n=2, 3.7%), and pneumonia (n=4, 7.4%). The most common isolated agent was C. albicans (n=27, 50%) and the others were C. parapsilosis (n=13, 24%), C. tropicalis (n=6, 11.1%), C. glabrata (n=3, 5.6%), C. lusitaniae (n=2, 3.7%), and unspecified Candida spp. (n=3, 5.6%). Fluconazole resistance was 7.4% among all isolates. Resistance against itraconazole, ketoconazole, anidulafungin, voriconazole and caspofungin were 33.3%, 12.5%, 11.1%, 5%, and 2.5%, respectively. Isolates presented intermediate resistance against itraconazole (41.7%), voriconazole (5.6%), and amphotericin B (3.7%) to varying extents. All of the isolates were susceptible to flucytosine. Conclusions: In our clinic, C. albicans and non-albicans Candida species were equally distributed and antifungal susceptibilities against major antifungal agents such as fluconazole, amphotericin B, and caspofungin were found considerably high.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of Candida species and antifungal susceptibilities among children with invasive candidiasis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Invasive fungal infections (IFIs) caused by yeast of the genus Candida are important causes of morbidity and mortality in both immunocompromised and hospitalised patients . Over the past two decades, Candida spp.…”

Section: Introductionmentioning

confidence: 99%

Invasive candidiasis and candidaemia in neonates and children: update on current guidelines

Tragiannidis

Tsoulas²,

Groll

2014

Mycoses

Self Cite

View full text Add to dashboard Cite

Invasive candidiasis (IC) and candidaemia are leading causes of infectious morbidity and mortality among immunocompromised paediatric patients and those admitted to intensive care units. Despite improvements in diagnosis, prevention and treatment, both mortality rates and the economic burden of disease still remain high. To address this issue, several international societies and organisations have proposed guidelines for the management of IC/candidaemia in both neonates and children. In this article, we review current recommendations of the Infectious Diseases Society of America, the European Conference on Infection in Leukaemia, the European Society of Clinical Microbiology and Infectious Diseases and the German Speaking Mycological Society/Paul-Ehrlich Society for Chemotherapy for the management and prevention of IC/candidaemia in children and neonates.

show abstract

“…Recent data suggests an increased incidence of non-albicans Candida species. As such, C. glabrata and Candida parapsilosis (C. parapsilosis) are now ranked as second in the Northern Europe and the United States [26,27] , and in Latin America and Southern Europe [28,29] , respectively. Some predisposing factors including central venous catheters (CVC), total parenteral nutrition (TPN), and prior azole exposure are proposed to result in the emergence of non-albicans Candida species.…”

Section: Problem On the Risementioning

confidence: 99%

Invasive candidiasis in critical care setting, updated recommendations from “Invasive Fungal Infections-Clinical Forum”, Iran

Elhoufi

Ahmadi

Asnaashari

et al. 2014

WJCCM

View full text Add to dashboard Cite

Invasive candidiasis (IC) bears a high risk of morbidity and mortality in the intensive care units (ICU). With the current advances in critical care and the use of widespectrum antibiotics, invasive fungal infections (IFIs) and IC in particular, have turned into a growing concern in the ICU. Further to blood cultures, some auxil- REVIEW 102November 4, 2014|Volume 3|Issue 4| WJCCM|www.wjgnet.com iary laboratory tests and biomarkers are developed to enable an earlier detection of infection, however these test are neither consistently available nor validated in our setting. On the other hand, patients' clinical status and local epidemiology data may justify the empiric antifungal approach using the proper antifungal option. The clinical approach to the management of IC in febrile, non-neutropenic critically ill patients has been defined in available international guidelines; nevertheless such recommendations need to be customized when applied to our local practice. Over the past three years, Iranian experts from intensive care and infectious diseases disciplines have tried to draw a consensus on the management of IFI with a particular focus on IC in the ICU. The established IFI-clinical forum (IFI-CF), comprising the scientific leaders in the field, has recently come up with and updated recommendation on the same (June 2014). The purpose of this review is to put together literature insights and Iranian experts' opinion at the IFI-CF, to propose an updated practical overview on recommended approaches for the management of IC in the ICU. Core tip: The present consensus statement has attempted to summarize the practical highlights regarding the management of Invasive Candidiasis (IC) in critical care setting. This easy-to-follow clinical pathway is expected to be not only of interest but also of clinical use for those who deal with the management of invasive fungal infections in hospital setting and especially the intensive care units. The focus of this paper is the concept of timely management of IC in critically ill patients.

show abstract

Invasive candidiasis: update on current pharmacotherapy options and future perspectives

Cited by 29 publications

References 118 publications

Evaluation of Candida species and antifungal susceptibilities among children with invasive candidiasis

Evaluation of Candida species and antifungal susceptibilities among children with invasive candidiasis

Invasive candidiasis and candidaemia in neonates and children: update on current guidelines

Invasive candidiasis in critical care setting, updated recommendations from “Invasive Fungal Infections-Clinical Forum”, Iran

Contact Info

Product

Resources

About